… up-front RT and TKI with TKI alone (or with salvage RT) in NSCLC patients with newly … brain
metastasis and EGFR mutation. RT followed by TKI or started within 4 weeks after EGFR-TKI …

… of advanced EGFR-mutant NSCLS with brain metastases … EGFR-TKIs and WBRT vs
EGFR-TKI alone in a retrospective cohort of advanced EGFR-mutant NSCLS with brain metastases. …

… EGFR-TKI) alone for the treatment of brain metastases … TKI-naïve patients with newly
diagnosed brain metastases, patients were excluded if they had prior EGFR-TKI use, had EGFR-TKI …

… Brain metastases (BM) are common in advanced non-small cell lung cancer (NSCLC), and
… –tyrosine kinase inhibitors (EGFR-TKIs) in preventing and treating BM in patients with EGFR …

… EGFR TKIs reported intracranial ORR of 66–88%, and patients with asymptomatic brain
metastases … Third-generation EGFR TKIs appear to have greater intracranial activity, with early …

… EGFR TKIs in EGFR BMs, there has been a lot of interest in combining EGFR TKIs with brain
… of erlotinib and WBRT in 40 patients with brain metastases from lung adenocarcinoma [38]. …

… alone for the patients with one to three intracranial metastatic lesions.18, 19 We therefore …
plus an EGFR TKI could have more benefit than an EGFR TKI alone in patients with EGFR …

… Here, we compared prognoses of patients with EGFR-TKI naïve EGFR-positive … EGFR-TKIs
at a single institution, we reviewed medical records of 205 patients with documented EGFR …

… mutations have been identified which are associated with significant sensitivity to EGFR
tyrosine kinase inhibitors (TKI) and correlate with improved outcome in patients with NSCLC …

… –tyrosine kinase inhibitor (EGFR-TKI) alone with EGFR-TKI plus whole-brain radiotherapy
(WBRT) for the treatment of brain metastases (BM) in patients with EGFR-mutated lung …